Gilead Sciences Inc.
Company Snapshot
Company Overview
Gilead Sciences, Inc. is a biopharmaceutical company offering medicines for HIV, viral hepatitis, COVID-19, and cancer. The company operates in a single business segment that focuses on discovering, developing, and commercializing innovative medicines in areas of unmet medical need. Gilead Sciences, Inc. offers several blockbuster drugs for the prevention and treatment of HIV, including Biktarvy, Genvoya, Descovy, and Odefsey. The cancer portfolio includes cell therapies (Yescarta and Tecartus) and ADC (Trodelvy). 2020 Gilead Sciences, Inc. acquired Trodelvy (sacituzumab govitecan-hziy), a Trop-2-directed ADC, by acquiring Immunomedics for approximately $21.0 billion deal value.
Financial Highlights (FY 2024)
This information is available for BCC Research members only.
Company's Business Segments
- HIV : Biktarvy, Genvoya, Descovy, Odefsey, Complera /Eviplera, Truvada, Stribild, Sunlenca, Veklury, Epclusa, Vemlidy, Harvon, Viread
- Oncology : Yescarta, Trodelvy, Tecartus
- Liver Disease : Ledipasvir/ Sofosbuvi, Sofosbuvir/Velpatasvir, Other HCV, Vemlidy, Viread, Other HBV/HDV
- Veklury : Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor
- Other : AmBisome, Letairis, Royalty, contract and other revenues
Applications/End User Industries
- Theapeutic Area
- Medicines
- Pipeline
- Research
- Clinical Trials
- Pharmaceutical Companies
